SHARON, Pa., June 1 /PRNewswire-FirstCall/ -- NanoLogix, Inc., (Pink Sheets: NNLX), a Nanobiotechnology company engaged in the research, development and commercialization of technologies for the production of bacteria and disease testing kits, alternative sources of fuel, cancer therapy and remediation of toxic materials, announced that it has filed a provisional patent application for its proprietary method of synergistically combining a bacteria-based hydrogen production method with excess industrial heat. The excess heat utilized by this method helps isolate hydrogen producing bacteria in the bacteria-based hydrogen production method. The bacterial hydrogen production process uses excess heat that is produced during standard usage of hydrogen production method, thereby reducing the cost of the hydrogen production by running two methods simultaneously and conserving energy. NanoLogix recently announced that preliminary data and results of a study which confirms laboratory proof-of-concept measurements have shown it possible to generate hydrogen in high yields via the use and adaptation of its intellectual property. In this study, the bioreactor produced biogas consisting of 50% hydrogen by volume, without any trace of methane. "NanoLogix intends to dominate the patent coverage for a variety of disruptive technologies at a time when the energy and healthcare industries are screaming for change," said David McClelland, President of NanoLogix. "We are seeing confirmation of this by the caliber of companies we are in discussions with who have expressed interest in our technology, in addition to significant progress we are making in our research collaborations," he added. Recently, NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively. Hydrogen reacts with oxygen to yield significant amounts of energy, and has the added benefit of not producing carbon dioxide as a by-product (the reaction between hydrogen and oxygen simply generates water vapor). NanoLogix believes they have discovered the most likely method for low cost production of massive quantities of hydrogen as an alternate energy source. NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. About NanoLogix NanoLogix, Inc., formerly known as Infectech (http://www.infectech.com), is a technology application innovator of biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally-friendly energy sources. NanoLogix is also engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. The Company's 31 patents can be viewed by visiting http://www.infectech.com/intellectual_property.php . About Nanotechnology The convergence of science, medicine and technology is on the cusp of yielding extraordinary breakthroughs. Today, patents that were once designed to identify bacteria have widespread applications across multiple markets. At the heart of this convergence is nature. All things begin and end with the building blocks of life. NanoLogix's portfolio of 31 patents have yielded a method vital to the development of biophasic system devices intended for medical purposes to cultivate and identify certain pathogenic microorganisms. The devices contain one or more components that suppress the growth of certain microorganisms while either promoting or not affecting the growth of other microorganisms. The FDA registered devices aid in the diagnosis of disease caused by the pathogenic microorganisms. Additional products include a method for low cost hydrogen production, a genomic cancer therapy and methods for cleaning up toxic environments using bioremediation. NanoLogix's patents have nanotechnology applications in medical drugs/devices, bio-defense sensors, hydrogen production, cancer treatment and bioremediation. Nanotechnology applications include Biochips embedded in small transportable devices for rapid bacteria identification of disease causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for rapid environmental microbial monitoring with bio-defense implications. Its hydrogen bioreactor research is designed to assist in worldwide energy independence and reduce pollution using renewable, environmentally-friendly energy sources. NanoLogix's FDA registered diagnostic test kits are designed to be used for the rapid identification of infectious human diseases and identify 34 disease-producing bacteria, including Tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. It therefore serves as the foundation for cancer therapy. NanoLogix's other patents include technology designed for use in the bioremediation of contaminated soil and water. This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward- statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
SOURCE NanoLogix, Inc.